ArticleClinica chimica acta; international journal of clinical chemistry2016
Detection of HIV-1 p24 antigen in patients with varying degrees of viremia using an ELISA with a photochemical signal amplification system.
Article in Clinica chimica acta; international journal of clinical chemistry, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 29 citations in OpenAlex.
- Distinguishing active HIV-1 infection from vaccine-induced seropositivity in HIV vaccine trial participants.Science advances · 2025Article
- Using common features of viruses and EVs for a novel EV-based lateral flow test for HIV.Extracellular vesicle · 2025Article
- HIV-1 diagnostic, prognostic and ART-resistance detection potential of selected MiRNAs.BMC infectious diseases · 2025Article
- Dinuclear Copper(II) Complexes of 2,6-Bis[(International journal of molecular sciences · 2025Article
- LM11A-31, a modulator of p75 neurotrophin receptor, suppresses HIV-1 replication and inflammatory response in macrophages.Experimental biology and medicine (Maywood, N.J.) · 2024Article
- Engineering CRISPR/Cas13 System against RNA Viruses: From Diagnostics to Therapeutics.Bioengineering (Basel, Switzerland) · 2022Review
- A pilot study to assess the performance of a rapid ultrasound particle agglutination method for the detection of HIV antibodies.Journal of immunoassay & immunochemistry · 2022Article
- Impact of Age and Gender Disparity on CD4+ Cell Counts to Control Disease Progression Using Specific HAART in HIV-1 Positive Patients: A Case-Control Study.Reviews on recent clinical trials · 2022Article
- Virus Detection: A Review of the Current and Emerging Molecular and Immunological Methods.Frontiers in molecular biosciences · 2021Review
- Laser ablation for pharmaceutical nanoformulations: Multi-drug nanoencapsulation and theranostics for HIV.Nanomedicine : nanotechnology, biology, and medicine · 2020Article
- Cell phone based colorimetric analysis for point-of-care settings.The Analyst · 2019Article
- Increased Sensitivity of HIV-1 p24 ELISA Using a Photochemical Signal Amplification System.Journal of acquired immune deficiency syndromes (1999) · 2015Article
- Comparison of various radioactive payloads for a human monoclonal antibody to glycoprotein 41 for elimination of HIV-infected cells.Nuclear medicine and biologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
backgroundWe describe a photochemical signal amplification method (PSAM) for increasing the sensitivity of enzyme-linked immunosorbent assays (ELISAs) for the detection of HIV-1 p24 antigen, and present a preliminary validation study on ELISA+PSAM technology for detection of HIV-1 p24 antigen in clinical samples.
methodsELISA+PSAM is compatible with commercially available microtiter plate readers, employs an inexpensive illumination device and the amplification takes around 10 min.
resultsThe PSAM technology not only increases the analytical sensitivity for detection of HIV-1 p24 antigen by approximately 40 times, but also significantly increases the clinical sensitivity of the ELISA: in instances where viral RNA load is <3000 copies/ml, conventional heat mediated immune complex disruption ELISA (HM-ELISA) cannot detect any HIV positive samples whereas HM-ELISA+PSAM can detect HIV infection in approximately half of the samples (clinical sensitivity is 52.63%). For viral RNA loads between 3000 and 30,000 copies/ml, the clinical sensitivities of the HM-ELISA and HM-ELISA+PSAM are 32.6% and 91.3%, and for that >30,000 copies/ml, clinical sensitivities of HM-ELISA and HM-ELISA+PSAM are 52.3% and 100%, respectively.
conclusionsThe HM-ELISA+PSAM represents an advancement in monitoring HIV-1 disease progression and treatment in the global healthcare setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.